MyVisionTest News Archive

Displaying news items tagged with wet AMD (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Double helix DNA
Feb 24, 2012
AMD has been one of the success stories of the genome revolution and is probably one of the best characterized of the complex trait diseases in terms of genetic predisposition. Besides age, genetic background is the most significant non-modifiable risk factor for all stages of AMD, while smoking is the most significant modifiable risk factor....

Full Article


Visudyne
Feb 17, 2012
A new study finds an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and response to treatment with photodynamic therapy (PDT) for age-related macular degeneration (AMD) in a Japanese population. Studies...

Full Article


DNA double-helix molecule
Feb 16, 2012
A new study finds that among patients with wet AMD those with higher risk genotypes response better to Lucentis (ranibizumab) therapy than patients with lower risk genotypes. Epidemiological and association studies have shown that both genetic and environmental factors play a major role in the development of AMD. Association studies have...

Full Article


Lucentis
Feb 15, 2012
Age-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. It is hoped that such research will define the genetic biomarker spectrum to allow treatment...

Full Article


Eylea
Jan 16, 2012
A phase 3 study of the efficacy of Eylea injections to treat neovascular AMD has shown sustained improvement in visual acuity at 96 weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a press release. In the first year of the parallel VIEW 1 and VIEW 2 studies, patients received Eylea (aflibercept, Regeneron Pharmaceuticals)...

Full Article


Intraocular pressure
Jan 14, 2012
Neovascular age-related macular degeneration (AMD) patients undergoing unilateral intravitreal Lucentis (ranibizumab) and/or Avastin (bevacizumab) injections are more likely to suffer intraocular pressure (IOP) elevation of at least 5 mmHg of 2 or more visits if they recieve a greater number of injections, according to a new study. Intravitreal...

Full Article


Avastin
Jan 14, 2012
Intraocular injections of anti–vascular endothelial growth factor (VEGF) agents have yielded dramatic improvements in the management of a wide variety of neovascular ocular diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion, and retinopathy of prematurity. These agents have thus become...

Full Article


Eylea
Jan 8, 2012
The US Food and Drug Administration (FDA) approved aflibercept ophthalmic solution (Eylea, Regeneron Pharmaceuticals Inc) for the treatment of neovascular ("wet") age-related macular degeneration (AMD) in November 2011. "Eylea is an important new treatment option for adults with wet AMD," said Edward Cox of the FDA. "It is a potentially...

Full Article


CATT trial logo
Jan 8, 2012
Avastin and Lucentis had equivalent effects on visual acuity at 1 year, accirding to the much anticipated Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) research group. Clinical trials have established the efficacy of Lucentis (ranibizumab) for the treatment of neovascular age-related macular degeneration (AMD). In...

Full Article


Avastin
Apr 22, 2011
Avastin (bevacizumab) is the most popular pharmacological treatment for neovascular age-related macular degeneration (AMD) among Medicare fee-for-service beneficiaries in the United States. Over the past 3 years, both Avastin (bevacizumab) and Lucentis (ranibizumab) have emerged as the most common therapies for neovascular AMD as reported by...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More